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While both blood and lymphatic vessels transport fluids and thus share many 
similarities, they also show functional and structural differences, which can be used to 
differentiate them. Specific visualization of lymphatic vessels has historically been and 
still is a pivot point in lymphatic research. Many of the proteins that are investigated 
by molecular biologists in lymphatic research have been defined as marker molecules, 
i.e. to visualize and distinguish lymphatic endothelial cells (LECs) from other cell types, 
most notably from blood vascular endothelial cells (BECs) and cells of the 
hematopoietic lineage. 
Among the factors that drive the developmental differentiation of lymphatic structures 
from venous endothelium, Prospero homeobox protein 1 (PROX1) is the master 
transcriptional regulator. PROX1 maintains lymphatic identity also in the adult 
organism and thus is a universal LEC marker. Vascular endothelial growth factor 













proliferation and migration. The major activator for VEGFR-3 is vascular endothelial 
growth factor-C (VEGF-C). However, before VEGF-C can signal, it needs to be 
proteolytically activated by an extracellular protein complex comprised of collagen and 
calcium binding EGF domains 1 (CCBE1) protein and the protease A disintegrin and 
metallopeptidase with thrombospondin type 1 motif 3 (ADAMTS3). 
This minireview attempts to give an overview of these and a few other central proteins 
that scientific inquiry has linked specifically to the lymphatic vasculature. It is limited in 
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Introduction 
The lymphatic system is involved in the maintenance of the body fluid balance 
(Dongaonkar et al., 2009), in immune cell trafficking (specifically in dendritic cell 
trafficking from tissues to lymph nodes; Miteva et al., 2010; Randolph et al., 2005), 
and in dietary lipid absorption from the intestine via the blind-ended central lymph 
vessels in the intestinal villi known as lacteals (Iqbal and Hussain, 2009). Similar to 
the blood vasculature (Aird, 2012), there is substantial heterogeneity and plasticity 













vessels are reflected in their molecular setup (Ulvmar and Mäkinen, 2016). Lymphatic 
research has entered the molecular era more than two decades ago with the discovery 
of the first lymphangiogenic growth factor VEGF-C (Joukov et al., 1996) and its 
receptor VEGFR-3 (Kaipainen et al., 1995), which was also used as the first lymphatic-
specific marker. The interest in lymphatic research has been increasing since due to 
the recognition that lymphatics are integral to many disease processes (Alitalo, 2011). 
However, the continuing discoveries of molecules that play important roles for 
lymphatic biology underline that our understanding of the molecular mechanisms of 
lymphatic development and function under both physiological and pathological 
settings is far from complete. 
Transcription factors SOX18, COUP-TFII, PROX1 and FOXC2 
The SOX18 transcription factor is perhaps the earliest involved in the specification of 
endothelial cells into the lymphatic lineage. It activates the expression of PROX1 
(Prospero Homeobox 1) in endothelial cells of the cardinal veins around E9.5 
(Francois et al., 2008). SOX18 cannot activate PROX1 alone, but needs cooperation 
from COUP-TFII, which is expressed throughout the venous system (Srinivasan et al., 
2007). Contrary to SOX18 expression, which appears to be needed only for the 
initiation of LEC specification, COUP-TFII and PROX1 continue to be strongly 
expressed in established lymphatic vessels (Francois et al., 2011), although only 
PROX1, but not COUP-TFII is necessary for the maintenance of the lymphatic identity 
(Johnson et al., 2008; Lin et al., 2010). 
PROX1 is expressed by several cell types like liver cells and many stem cells, but in 
the vascular compartment, it is largely specific for lymphatic endothelial cells, although 













venous (Bazigou et al., 2011) and the cardiac (Rodriguez-Niedenführ et al., 2001) 
valves. PROX1 is the key transcription factor for the early steps of LEC differentiation 
from the embryonic veins (Wigle and Oliver, 1999) and remains required for lymphatic 
identity (Johnson et al., 2008). The over-expression of PROX1 in BECs modifies their 
expression patterns to resemble LECs (Hong et al., 2002; Petrova et al., 2002), 
including the upregulation of the gene encoding VEGFR-3, that is seen in the cardinal 
vein endothelial cells which are committed to LEC differentiation (Wigle et al., 2002). 
The FOXC2 transcription factor becomes important during later stages of the 
lymphatic development. It controls the interaction between pericytes and LECs 
(Petrova et al., 2004), and is required together with NFATc1 for the lymphatic 
remodeling and maturation including the formation of lymphatic valves in the 
precollectors and collectors (Norrmén et al., 2009). 
The major mitogenic receptor on LECs: VEGFR-3 
VEGFR-3 (previously also called FLT4) is the quintessential lymphatic receptor 
tyrosine kinase. However, early developing blood vessels (from day 8 to 10) also 
express significant amounts of VEGFR-3. In mice, loss of VEGFR-3 leads to 
embryonic death at E10.5 due to cardiovascular defects (Dumont et al., 1998). Unlike 
VEGFR-3 deletion, the simultaneous deletion of both VEGFR-3 ligands (VEGF-C and 
VEGF-D) in mouse embryos does not, for the most part, affect blood vessels, with the 
exception of VEGF-C-induced BEC migration, which is important for the development 
of the coronary vasculature (Chen et al., 2014a, 2014b). Nevertheless, most of the 
early embryonic function of VEGFR-3 does apparently not require activation by ligands 
of the VEGF family (Haiko et al., 2008). Hence it remains unclear, what mechanism 













Heterodimerization with VEGFR-2 in response to VEGF-A (Dixelius et al., 2003; 
Nilsson et al., 2010) could enable VEGFR-3 signaling, but ligandless baseline 
signaling or alternative activation mechanisms involving integrins and 
mechanoinduction could also play a role (Galvagni et al., 2010; Planas-Paz et al., 
2012; Wang et al., 2001). 
VEGFR-3 expression declines on BECs during the period of lymphatic budding from 
venous endothelium and the establishment of the first lymphatic structures, which 
starts around E10-E10.5. By day 14.5, it is seen mostly on lymphatics (Kaipainen et 
al., 1995) with the exception of a few vascular specializations, where it persists into 
adulthood, such as fenestrated vessels (Partanen et al., 2000) and some high 
endothelial venules (Kaipainen et al., 1995). Mutations in Flt4 cause Type IA 
hereditary lymphedema (Milroy disease), which is the most common form of primary 
lymphedema in humans. Most of these mutations inactivate the tyrosine kinase activity 
of VEGFR-3 (Karkkainen et al., 2000) and in mice, functionally analogous mutations 
result as well in a lymphedema phenotype (Karkkainen et al., 2001). 
Both LECs and BECs express VEGFR-2 
VEGFR-2 is the tyrosine kinase receptor, which mediates most - if not all - functions 
of the classic hemangiogenic growth factor VEGF-A (Simons et al., 2016). However, 
VEGFR-2 can also be activated by the mature forms of VEGF-C and VEGF-D (the 
different forms of VEGF-C and VEGF-D are discussed in the paragraph VEGF-D is a 
dissimilar twin of VEGF-C and the following). Because VEGFR-2 is also expressed at 
moderate levels on most LECs, VEGF-A replaces VEGF-C as medium supplement in 
many LEC culture protocols (Lonza, 2017; PromoCell, 2017). Lymphatic hyperplasia 













VEGFR-2-monospecific VEGF-E (Wirzenius et al., 2007). Despite lymphatic 
hyperplasia, there was no increase in lymphatic numbers in VEGF-E overexpressing 
mice and in mouse ears transduced with a VEGF-A-expressing adenovirus. This led 
to the hypothesis that VEGFR-2 signalling causes only circumferential growth of 
lymphatic vessels, while VEGFR-3 signalling causes the generation of new vessels by 
sprouting lymphangiogenesis. VEGF-A-induced lymphangiogenesis might also be 
indirectly mediated by upregulating VEGF-C expression in BECs (Skobe et al., 1999; 
Skobe & Detmar, 2000) or in macrophages (Harvey and Gordon, 2012), which can be 
recruited e.g. by VEGF-A via VEGFR-1 (Hiratsuka et al., 1998). However, it remains 
unclear which mechanisms are involved in vivo. 
VEGF-C is the primary lymphangiogenic growth factor 
VEGF-C is the primary ligand that activates VEGFR-3 (see Figure 1). The sprouting 
of endothelial cells from the embryonic veins is crucially dependent on VEGF-C. Its 
absence leads to the failure of lymph sac formation and embryonic death around E16.5 
(Hagerling et al., 2013; Karkkainen et al., 2004). Also in the heterozygous state, 
VEGF-C deficiency leads neonatally to severe complications due to insufficient lacteal 
function and resulting chylous ascites (Karkkainen et al., 2004). Although rare, 
mutations in the human VEGFC gene have been shown to be responsible for some 
forms of hereditary lymphedema (Balboa-Beltran et al., 2014; Gordon et al., 2013). 
VEGF-C is first produced in larger amounts in regions juxtaposed to the prospective 
locations of lymphatic sprouting (e.g. the mesenchyme around the developing 
metanephros and in the jugular area; Karkkainen et al., 2004; Kukk et al., 1996) and 













and Oliver, 2014). However, direct evidence of a VEGF-C gradient formation is 
lacking, and it is also still unknown how VEGF-C expression is induced. 
Some lymphatic networks are not generated by lymphangiogenesis (the growth of 
lymphatics from pre-existing vessels), but instead by lymphvasculogenesis (the 
differentiation and assembly from non-venous precursor cells). Lymphvasculogenesis 
appears to be used in different organs and by different organisms to various degrees, 
but at least in mice, the lymphvascularization of the heart (Klotz et al., 2015), the 
mesentery (Stanczuk et al., 2015) and the skin (Martinez-Corral et al., 2015) involves 
lymphvasculogenesis. The molecular orchestration of this process is under 
investigation, and similar to lymphangiogenesis, VEGF-C appears to be required. 
VEGF-D is a dissimilar twin of VEGF-C 
Together with VEGF-D (Achen et al., 1998), which had been first described as c-fos-
induced growth factor (FIGF) (Orlandini et al., 1996), VEGF-C forms a subgroup within 
the protein family of vascular endothelial growth factors. Unlike the other VEGFs, both 
VEGF-C and VEGF-D are produced as pro-proteins and require a multistep proteolytic 
cleavage before they become active. The first (C-terminal) cleavage is similarly 
executed for both VEGF-C and VEGF-D by furin or the proprotein convertases PC5 
and PC7 (McColl et al., 2007; Siegfried et al., 2003). While the first cleavage is 
constitutive, the second (N-terminal) cleavage is tightly regulated and depends on 
different enzymes for VEGF-C and VEGF-D (Bui et al., 2016). 
Both VEGF-C and VEGF-D appear similarly lymphangiogenic in a variety of models 
like transgenic mice (Jeltsch et al., 1997; Veikkola et al., 2001), adenoviral 













al., 2003; Oh et al., 1997). However, unlike Vegfc, Vegfd can be deleted, at least in 
mice, without appreciable consequences for the lymphatic system during 
embryogenesis (Baldwin et al., 2005). However, adult Vegfd-deleted mice present with 
initial dermal lymphatics of reduced size and functionality, implying a role of VEGF-D 
during adult lymphangiogenesis, specifically perhaps during wound healing (Paquet-
Fifield et al., 2013). In several in vivo models, VEGF-D shows a stronger and distinct 
angiogenic effect compared to VEGF-C (Duong et al., 2014; Leppanen et al., 2011; 
Song et al., 2007; Rissanen, 2003). This agrees with data showing that the maximally 
processed form of VEGF-D does – differently to VEGF-C – not anymore activate 
VEGFR-3, but only the angiogenic receptor VEGFR-2 (Leppanen et al., 2011). The 
difference between VEGF-C and VEGF-D has been pinpointed to a diverging role of 
the N-terminal α-helix for receptor binding (Davydova et al., 2016). However, many of 
these binding studies have been performed with truncated and/or mutated forms of 
VEGF-D, making it difficult to extrapolate to the in-vivo situation. Similarly, in 293EBNA 
cells, processing of VEGF-D results in 2.5 times more of the VEGFR-3-binding form 
compared to the VEGFR-2-binding form (Stacker et al., 1999), but it is completely 
unknown whether and how much of the VEGFR-2-specific form is generated in vivo . 
VEGF-C activation requires CCBE1 and ADAMTS3 
During development, a disintegrin and metalloproteinase with thrombospondin motifs 
3 (ADAMTS3) is indispensable for the proteolytic activation of pro-VEGF-C, resulting 
in the mature, active VEGF-C (Jeltsch et al., 2014). ADAMTS3 was originally assumed 
to be a procollagen II processing enzyme (Fernandes et al., 2001), but Adamts3-
deleted mice do not show procollagen processing defects, but instead a prenatally 













ADAMTS3 requires the collagen- and calcium-binding EGF domains 1 (CCBE1) 
protein (Bos et al., 2011; Bui et al., 2016; Jeltsch et al., 2014; Le Guen et al., 2014) 
and mutations in the CCBE1 gene can be responsible for Hennekam Syndrome, a 
human hereditary condition characterized by generalized lymphedema (Alders et al., 
2013, 2009). Recent studies have delineated details of the molecular requirement of 
CCBE1 for ADAMTS3 function and shown that also ADAMTS3 mutations can be the 
cause of hereditary lymphedema conditions (Brouillard et al., 2017; Jha et al., 2017). 
Differently to VEGF-C, VEGF-D is not activated by ADAMTS3/CCBE1 (Bui et al., 
2016; Jeltsch et al., 2014), but instead by plasmin, indicating that VEGF-D would 
rather act during inflammation- or wound-healing associated lymphangiogenesis (Bui 
et al., 2016). 
Differences between human and murine VEGFR-3 signaling  
The first cDNA of VEGFC was isolated from a human library (Joukov et al., 1996). 
While the early confirmations of its lymphatic function used human proteins (Jeltsch et 
al., 1997; Oh et al., 1997), most experimental studies about the lymphatic system are 
performed nowadays in mice. Therefore, it is important to highlight distinct differences 
between the molecular interactions of the human and the corresponding murine 
molecules of the VEGFR-3 signaling pathway. While mature human VEGF-D can bind 
to both human VEGFR-2 and human VEGFR-3, mature mouse VEGF-D has been 
reported to bind only to mouse VEGFR-3, but not to mouse VEGFR-2 (see Figure 1) 
(Baldwin et al., 2001). A similarly important difference exists for VEGFR-3. Humans 
have two functionally diverging splice isoforms: VEGFR-3s (short isoform) and 













primate species (Hughes, 2001). However, it remains speculative whether these 
dissimilarities result in morphological or functional differences. 
Unorthodox VEGF-C signaling 
While lymphatics and VEGF-C expression can be found in almost all tissues during 
development, not all VEGF-C/VEGFR-3 signaling targets endothelial cells. During 
brain development, neuronal progenitor cells in the olfactory bulb and glial precursor 
cells in the optic nerve respond to VEGF-C exposure with proliferation (Le Bras et al., 
2006). Also in adult mice, VEGF-C signaling appears to be able to stimulate 
neurogenesis (Han et al., 2015), and, in zebrafish, VEGF-C appears crucial for motor 
neuron axon growth (Kwon et al., 2013). In the eye, corneal epithelial cells express 
VEGFR-3, where it can act as a decoy receptor removing lymphangiogenic and 
angiogenic factors thereby maintaining avascularity (Cursiefen et al., 2006). 
Unsurprisingly, due to their common ancestry, quite a few cells of hematopoietic origin 
express VEGFR-3 and react to VEGF-C. Such cells include hematopoietic stem cells 
(Fang et al., 2016; Hamada et al., 2000) and megakaryocyte precursors (Thiele et al., 
2012). The expression of VEGFR-3 by corneal dendritic cells (Hamrah et al., 2003) 
and by conjunctival cells of the monocyte/macrophage lineage (Hamrah et al., 2004) 
has been suggested to play a role for the immune response in the eye. Macrophages 
not only can express VEGFR-3, but they also can secrete the VEGFR-3 ligand VEGF-
C. In the skin, macrophages intriguingly appear to regulate the salt balance of body 
fluids by secreting VEGF-C, which in turn has been proposed to regulate the lymphatic 
volume and gateway function between the hyperosmotic interstitium and normosmolar 
blood (Machnik et al., 2009). VEGFR-3 can also be expressed by tumor associated 













cell metastasis (Su et al., 2006) and leukemic cell growth and proliferation (Dias et al., 
2002) by signaling through the VEGFR-3 present on the tumor cells. However, this 
notion has been challenged for solid tumors. Poor antibody specificity is likely 
responsible for most of the VEGFR-3 signals from tumor cells, while true-positive 
VEGFR-3 signals originate predominantly from endothelial cells (Petrova et al., 2008; 
Smith et al., 2010), where VEGFR-3 signaling promotes both tumor angiogenesis 
(Tammela et al., 2008) and tumor lymphangiogenesis (Mandriota et al., 2001; 
Karpanen et al., 2001; Skobe et al., 2001), which results in increased metastasis. 
Co-receptors 
Neuropilin-1 (NRP1) and neuropilin-2 (NRP2) have been first described as 
transmembrane proteins of neuronal cells, in which they regulate the growth of 
dendrites and axons together with their different semaphorin ligands, which act either 
as attractants or repellents (Schwarz and Ruhrberg, 2010). Both NRP1 and NRP2 are 
also expressed by endothelial cells, with NRP1 more prominently on arteries and 
NRP2 more prominently on LECs and veins (Herzog et al., 2001; Yuan et al., 2002). 
They act as co-receptors for VEGF ligands by stabilizing the growth factor/receptor 
complex, but likely do not exercise a signaling function in endothelial cells (Guo and 
Vander Kooi, 2015). While virtually all VEGF family members have been seen to 
interact with NRP1 (and most with NRP2), the VEGF-A/NRP1 (Kawamura et al., 2008) 
and the VEGF-C/NRP2 (Xu et al., 2010) interactions appear to be significant both in 
vivo and in vitro (Karpanen et al., 2006). Similar to the neuropilins, α5β1 integrin (Wang 
et al., 2001; Zhang et al., 2005) and syndecan-4 (Johns et al., 2016) are known co-
receptors for VEGFR-3. They can enrich the effective cell surface concentration of 













pressure-sensitive (Planas-Paz et al., 2012). Similarly, VEGFR-2 signalling can be 
enhanced by interaction with αvβ3 integrin (Soldi et al., 1999) and perlecan (Zoeller et 
al., 2009). 
LYVE-1 and podoplanin 
When endothelial structures are immunohistochemically interrogated, the expression 
of the cell surface glycoproteins LYVE-1 and podoplanin (PDPN) are good indicators 
of lymphatic nature. Apart from LECs, LYVE-1 is expressed also on liver BECs 
(Carreira et al., 2001) and on certain macrophages (Schledzewski et al., 2006), but it 
is generally a useful marker to identify lymphatic capillaries (Banerji et al., 1999). 
LYVE-1 expression is decreased on lymphatic pre-collectors and absent from 
collectors (Lutter et al., 2012). LYVE-1 is a receptor for hyaluronic acid and functions 
in dendritic cell entry into the lymphatics (Johnson et al., 2017). Similar to LYVE-1, 
PDPN is frequently used in the immunohistochemical detection of lymphatics 
(Breiteneder-Geleff et al., 1999). PDPN was originally identified from cells of the 
osteoblastic lineage (Wetterwald et al., 1996) and podocytes, where it is important for 
the formation of the glomerular filtration barrier of the kidney (Matsui et al., 1999). 
PDPN is not required for the early steps of lymphatic development and is e.g. also 
absent from the first LECs that emigrate from the cardinal veins (initial LECs or iLECs; 
see Figure 2) (Hagerling et al., 2013). PDPN rather appears to play a later role in 
lymphatic patterning (Schacht et al., 2003) and separation from the blood vasculature 













The ANG/TIE system is an important signaling component controlling endothelial cell 
behavior in both angiogenesis and lymphangiogenesis. Like the VEGF receptors, TIE 
receptor expression is mostly restricted to endothelial cells with the notable exception 
of some hematopoietic cells (Batard et al., 1996). No ligand has been identified for 
TIE1 and it is thus considered to be an orphan receptor. It contributes to signaling in 
concert with TIE2, which is the receptor for all known angiopoietins (see Figure 1). 
Genetic targeting of Tie1 is embryonically lethal and shows lymphatic abnormalities 
resulting in edema which arises from dysregulated lymph sac formation (D’Amico et 
al., 2010), defects in lymphatic vessel remodeling, collecting vessel formation and 
valve morphogenesis (Shen et al., 2014; Qu et al., 2015). In adult mice, however, Tie1 
ablation is well tolerated (D’Amico et al., 2014). Deletion of Ang2 results in defective 
collecting lymphatic vessel formation (Dellinger et al., 2008) and a smaller diameter of 
lymphatic capillaries without any noticeable effect in the early lymphatic development 
(Shen et al., 2014). Interestingly, Ang1 can rescue the lymphatic abnormalities 
observed in the Ang2 deleted mice (Dellinger et al., 2008). However, no apparent 
effect on lymphatic vasculature is observed in the Tie2 deleted mice (Shen et al., 
2014). 
ANG ligands can signal in two different configurations. The TIE receptors from two 
cells in close proximity can become ligated by ANG ligands (trans complexes). 
Alternatively, TIE receptors can form complexes within one cell triggered by e.g. 
matrix-bound ANG ligands (cis complexes) (Fukuhara et al., 2008; Saharinen et al., 













demonstrate, that the biological response within the ANG/TIE signaling is complex and 
context-dependent (reviewed by Eklund et al., 2017). 
Conclusions 
While the growing interest in lymphatic research has spawned many searches for 
“lymphatic” molecules (Hirakawa et al., 2003; Nelson et al., 2007; Petrova et al., 2002), 
the recent discovery of the essential functions of CCBE1 and ADAMTS3 for lymphatic 
development shows that we likely have not yet identified all important molecules in this 
field and that some surprises still lie ahead. This minireview is focused on the most 
central molecules (summarized in Table 1) skipping many essential molecules like 
those for the interaction of LECs with cells of the immune system (e.g. CCL21 for 
dendritic cell migration) (Russo et al., 2016; Vaahtomeri et al., 2017; Weber et al., 
2013) and those for pathological lymphangiogenesis, in which VEGF-C and VEGF-D 
are activated differently compared to developmental lymphatic growth (Bui et al., 2016; 
McColl et al., 2003). The designation of the LEC markers and the identification of 
lymphatic vessels are not without pitfalls. While the expression of commonly used LEC 
markers (VEGFR-3, PROX1, LYVE-1, PDPN) is largely restricted to LECs unlike the 
expression of general endothelial markers like PECAM-1 (CD31) (Parums et al., 1990; 
Sawa et al., 1998) or VE-cadherin (Baluk et al., 2007; Lampugnani et al., 1992), none 
of them is entirely exclusive for LECs. Unequivocal identification of lymphatic vessels 
requires therefore a combination of markers, and guidelines have been published, e.g. 
for the lymphatics of the human eye (Schrödl et al., 2015; Schroedl et al., 2014). To 
identify not only lymphatic structures but also their subtypes such as collector, valve 













podoplanin are frequently used LEC surface markers, which show a heterogeneous 
expression depending on the vessel caliber.  
The list of molecules with a lymphatic connection will continue to grow over the next 
years. From the medical perspective, almost every molecule in that list, once 
sufficiently understood, represents a possibility for therapeutic intervention. A few 
promising interventions are ongoing at the pharmaceutical level (Eiger 
BioPharmaceuticals, 2016; Herantis Pharma Plc, 2016). Beyond these, the growing 
precision of genome editing tools might in the future open the door for the correction 
of hereditary lymphatic conditions. 
A recent in-depth general review beyond the scope of this minireview is Vaahtomeri 
et al. (2017). Additionally, several review articles treat specific focus areas like the 
relationship of lymphatics with the cardiovascular system (Aspelund et al., 2016), the 
embryonic development of the lymphatic system (Koltowska et al., 2013), lymphatic 
tissue engineering (Schaupper et al., 2016), lymphatic diseases (Wang and Oliver, 
2010), therapeutic prospects (Zheng et al., 2014), and VEGF-C (Rauniyar et al., 2018). 
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Figure 1. Frequently encountered growth factors, receptors and co-receptors in 
endothelial cell biology. Both the VEGF receptors and the TIE receptors are the 
major signalling receptors for endothelial cells and they are for the most part specific 
for endothelial cells. VEGF receptors are supported by neuropilins, integrins and 
heparan sulfate proteoglycan (HSPG) co-receptors, which stabilize the growth factor 
receptor interaction and enhance signalling. The cartoon depicts the receptor domain 
organization, and known ligand-receptor interactions for the VEGF receptor tyrosine 
kinases and neuropilin co-receptors. From the integrin and HSPG co-receptor groups, 
not all known interacting co-receptors are included. In addition to the mammalian 
growth factor ligands also snake venom VEGFs (collectively known as VEGF-F) and 
viral VEGFs (collectively known as VEGF-E) are shown. Ligand-receptor interactions 
are not always conserved between orthologs of different mammalian species. The 
dotted arrows indicate absent interaction in some species or for some isoforms. To 
enhance clarity, interaction arrows are differently colored according to receptor group. 
The arrows of HSPG co-receptors connects them to their interacting VEGF receptors 
since the direct interaction of VEGF ligand and HSPG has not been shown in all cases. 
All VEGFs are – as well as the VEGF-C activators CCBE1 and ADAMTS3 – ill-suited 
as marker molecules due to their secreted nature. Note, that the short isoform of 
VEGFR-3 (VEGFR-3s) has been seen so far only in higher primates including humans. 














Figure 2. Key and marker molecules in the development of the lymphatic 
system. In mice, expression of SOX18 and COUP-TFII in the embryonic veins induces 
PROX1 expression at around E9.5 in a subset of venous endothelial cells. PROX1-
expressing lymphatic progenitor cells are specified to become lymphatic endothelial 
cells. PROX1-expressing venous endothelial cells (shown in purple) emigrate upon 
VEGFR-3-mediated VEGF-C signals. These initial LECs (iLECs, shown in red) 
assemble into the earliest lymphatic structures ("lymph sacs", shown in olive), which 
mature and expand to form a hierarchical lymphatic vascular network with capillaries 
(in green) and collecting vessels (in cyan). The yellow parts of the lymphatic network 
are not of venous origin: for a long time, it was thought, that lymphatics develop 
exclusively from the venous-derived early lymphatic structures by sprouting 
lymphangiogenesis. However, there is substantial evidence that e.g. the mesenteric 
lymphatic network is assembled from differentiating, non-venous precursors 













differentiation mechanisms seem to contribute to lymphvascularization (Martinez-
Corral et al., 2015). The ruler indicates the approximate starting times of the main 
developmental events in days of mouse embryonic development, but there are both 
significant spatial differences and temporal overlaps. The color labeling of the 













Table 1. Selected key molecules in lymphatic research and their properties. Listed from top to bottom and separated by 
background color are receptor tyrosine kinases, other transmembrane receptors, secreted growth factors, proteases/protease 
cofactors and transcription factors. 
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